Collapse of the tumor stroma is triggered by IL-12 induction of Fas

Molecular Therapy

Volumn 21, Issue 7, 2013, Pages 1369-1377

  Kerkar, Sid P ^a   Leonardi, Anthony J ^a   Van Panhuys, Nicolas ^b   Zhang, Ling ^a   Yu, Zhiya ^a   Crompton, Joseph G ^a   Pan, Jenny H ^a   Palmer, Douglas C ^a   Morgan, Richard A ^a   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MOUSE; NONHUMAN; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; UPREGULATION;

MURINAE; MUS;

EID: 84879696103     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.58     Document Type: Article

References (43)

1. Bronte, V (2009). Myeloid-derived suppressor cells in infammation: uncovering cell subsets with enhanced immunosuppressive functions. Eur J Immunol 39: 2670-2672.
2. Gabrilovich, DI, Ostrand-Rosenberg, S and Bronte, V (2012). Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 12: 253-268.
3. Kerkar, SP and Restifo, NP (2012). Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 72: 3125-3130.
4. Demaria, S, Pikarsky, E, Karin, M, Coussens, LM, Chen, YC, El-Omar, EM et al. (2010). Cancer and infammation: promise for biologic therapy. J Immunother 33: 335-351.
5. Kerkar, S P, Muranski, P, Kaiser, A, Boni, A, Sanchez-Perez, L, Yu, Z et al. (2010). Tumor-specifc CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res 70: 6725-6734.
6. Wagner, HJ, Bollard, CM, Vigouroux, S, Huls, MH, Anderson, R, Prentice, HG et al. (2004). A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specifc T cells. Cancer Gene Ther 11: 81-91. (Pubitemid 38141770)
7. Chinnasamy, D, Yu, Z, Kerkar, SP, Zhang, L, Morgan, RA, Restifo, NP et al. (2012). Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 18: 1672-1683.
8. Chmielewski, M, Kopecky, C, Hombach, AA and Abken, H (2011). IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 71: 5697-5706.
9. Kerkar, SP and Restifo, NP (2012). The power and pitfalls of IL-12. Blood 119: 4096-4097.
10. Pegram, HJ, Lee, JC, Hayman, EG, Imperato, GH, Tedder, TF, Sadelain, M et al. (2012). Tumor-targeted T cells modifed to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119: 4133-4141.
11. Zhang, L, Kerkar, SP, Yu, Z, Zheng, Z, Yang, S, Restifo, NP et al. (2011). Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther 19: 751-759.
12. Kerkar, SP, Goldszmid, RS, Muranski, P, Chinnasamy, D, Yu, Z, Reger, RN et al. (2011). IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 121: 4746-4757.
13. Zhao, X, Bose, A, Komita, H, Taylor, JL, Kawabe, M, Chi, N et al. (2011). Intratumoral IL-12 gene therapy results in the crosspriming of Tc1 cells reactive against tumor-associated stromal antigens. Mol Ther 19: 805-814.
14. Katz, JB, Muller, AJ and Prendergast, GC (2008). Indoleamine 2, 3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 222: 206-221. (Pubitemid 351430372)
15. Gabrilovich, DI and Nagaraj, S (2009). Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174.
16. Spiotto, MT, Rowley, DA and Schreiber, H (2004). Bystander elimination of antigen loss variants in established tumors. Nat Med 10: 294-298. (Pubitemid 38667621)
17. Zhang, B, Bowerman, NA, Salama, JK, Schmidt, H, Spiotto, MT, Schietinger, A et al. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204: 49-55. (Pubitemid 46148755)
18. Liotta, LA and Kohn, EC (2001). The microenvironment of the tumour-host interface. Nature 411: 375-379.
19. Motz, GT and Coukos, G (2011). The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11: 702-711.
20. Gajewski, TF, Meng, Y, Blank, C, Brown, I, Kacha, A, Kline, J et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145. (Pubitemid 44401498)
21. Zou, W (2005). Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274. (Pubitemid 40488632)
22. Kraman, M, Bambrough, PJ, Arnold, JN, Roberts, EW, Magiera, L, Jones, JO et al. (2010). Suppression of antitumor immunity by stromal cells expressing fbroblast activation protein-alpha. Science 330: 827-830.
23. Guiducci, C, Vicari, AP, Sangaletti, S, Trinchieri, G and Colombo, MP (2005). Redirecting in vivo elicited tumor infltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446. (Pubitemid 40524630)
24. Listopad, JJ, Kammertoens, T, Anders, K, Silkenstedt, B, Willimsky, G, Schmidt, K et al. (2013). Fas expression by tumor stroma is required for cancer eradication. Proc Natl Acad Sci USA 110: 2276-2281.
25. Siegel, RM, Chan, FK, Chun, HJ and Lenardo, MJ (2000). The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol 1: 469-474.
26. Liu, K, Caldwell, SA and Abrams, SI (2005). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res 65: 4376-4388. (Pubitemid 40775677)
27. Gattinoni, L, Lugli, E, Ji, Y, Pos, Z, Paulos, CM, Quigley, MF et al. (2011). A human memory T cell subset with stem cell-like properties. Nat Med 17: 1290-1297.
28. Boursalian, TE and Fink, PJ (2003). Mutation in fas ligand impairs maturation of thymocytes bearing moderate affnity T cell receptors. J Exp Med 198: 349-360. (Pubitemid 36987860)
29. Sun, M, Ames, KT, Suzuki, I and Fink, PJ (2006). The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 177: 1481-1491. (Pubitemid 44092481)
30. Trinchieri, G (2003). Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146. (Pubitemid 37328691)
31. O'Garra, A and Murphy, KM (2009). From IL-10 to IL-12: how pathogens and their products stimulate APCs to induce T(H)1 development. Nat Immunol 10: 929-932.
32. Colombo, MP and Trinchieri, G (2002). Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168. (Pubitemid 34229390)
33. Zitvogel, L and Lotze, MT (1995). Role of interleukin-12 (IL12) as an anti-tumour agent: experimental biology and clinical application. Res Immunol 146: 628-638. (Pubitemid 26054861)
34. Weiss, JM, Subleski, JJ, Wigginton, JM and Wiltrout, RH (2007). Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther 7: 1705-1721. (Pubitemid 350157496)
35. Bhardwaj, N, Seder, RA, Reddy, A and Feldman, MV (1996). IL-12 in conjunction with dendritic cells enhances antiviral CD8+ CTL responses in vitro. J Clin Invest 98: 715-722. (Pubitemid 26349176)
36. Klinke DJ 2nd, Cheng N, Chambers E. (2012). Quantifying crosstalk among interferon-gamma, interleukin-12, and tumor necrosis factor signaling pathways within a TH1 cell model. Sci Signal 5: ra32.
37. Hahne, M, Rimoldi, D, Schröter, M, Romero, P, Schreier, M, French, LE et al. (1996). Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366. (Pubitemid 26391458)
38. Zeytun, A, Hassuneh, M, Nagarkatti, M and Nagarkatti, PS (1997). Fas-Fas ligand-based interactions between tumor cells and tumor-specifc cytotoxic T lymphocytes: a lethal two-way street. Blood 90: 1952-1959. (Pubitemid 27377306)
39. Wigginton, JM, Park, JW, Gruys, ME, Young, HA, Jorcyk, CL, Back, TC et al. (2001). Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis. J Immunol 166: 1156-1168. (Pubitemid 32060275)
40. Hwu, P and Rosenberg, SA (1994). The use of gene-modifed tumor-infltrating lymphocytes for cancer therapy. Ann N Y Acad Sci 716: 188-97; discussion 197.
41. June, C, Rosenberg, SA, Sadelain, M and Weber, JS (2012). T-cell therapy at the threshold. Nat Biotechnol 30: 611-614.
42. Brenner, MK (2012). Will T-cell therapy for cancer ever be a standard of care? Cancer Gene Ther 19: 818-821.
43. Kerkar, SP, Sanchez-Perez, L, Yang, S, Borman, ZA, Muranski, P, Ji, Y et al. (2011). Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. J Immunother 34: 343-352.